AnaptysBio Prepares for a Potential Gear Shift

There wasn't much financial activity to report during the second quarter of 2019, but it was still a rough one for AnaptysBio (NASDAQ: ANAB) and its lead candidate, etokimab. Positive midstage clinical trial results that the company announced in early June didn't ignite any fireworks for the stock, but early results from a similar new drug candidate that Regeneron (NASDAQ: REGN) is developing took a heavy toll.